Glycorex Transplantation is a brand that has revolutionized the field of transplantation and autoimmune disease treatment with their molecular level nanosurgical technology. They have developed a method that selectively removes antibodies in the blood, allowing for effective management of blood donor blood and improved outcomes in transplantation. Glycorex's flagship product, Glycosorb® ABO, has been used in over 6,000 transplants across four continents, enabling blood group incompatible transplants with excellent short- and long-term results.

This not only saves lives but also has positive health economic effects, as each kidney transplant using Glycosorb® ABO can save about 150 dialysis treatments per year. In total, the brand estimates to have saved over 900,000 dialysis treatments annually. Another area where Glycorex excels is in blood group incompatible stem cell transplants.

Their technology helps reverse complications that can arise during the formation of red blood cells, allowing the transplanted stem cells to mature and form healthy blood cells. With their proven success, Glycorex is now expanding into new application areas, continuing to innovate and improve health outcomes globally